Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery
This study demonstrates the utility of TnT and NT-ProBNP as negative predictors to exclude CA in a screening population with a history of surgery for CTS.
Authors
- Finn Gustafsson (ORCID: https://orcid.org/0000-0003-2144-341X)
- Oscar Westin (ORCID: https://orcid.org/0000-0002-5621-6594)
- Navid Noory (ORCID: https://orcid.org/0000-0001-5486-6588)
- Matthew J. Maurer (ORCID: https://orcid.org/0000-0002-1867-0526)
- Emil Loldrup Fosbøl (ORCID: https://orcid.org/0000-0002-2048-4167)
Institutions
- Columbia University Irving Medical Center (US)
- Rigshospitalet (DK)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.ijcard.2024.132469
- Citations
- 8
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- Pfizer
- AstraZeneca
- Alnylam Pharmaceuticals
- Prothena
- Erik og Susanna Olesens Almenvelgørende Fond
- National Institutes of Health